Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.72 |
| ▸ | CDK2 | P24941 | 5/20 | 0.69 |
| ▸ | KDR | P35968 | 4/20 | 0.69 |
| ▸ | JAK2 | O60674 | 2/20 | 0.57 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22489335 | 0.94 | EGFR (0.72) | EGFRCDK2KDRJAK2AURKB | |
| SCHEMBL22489260 | 0.88 | EGFR (0.64) | EGFRCDK2KDRJAK2AURKB | |
| Hydrochloric Acid SCHEMBL22464989 | 0.88 | EGFR (0.63) | EGFRCDK2KDRJAK2AURKB | |
| SCHEMBL16339559 | 0.87 | EGFR (0.78) | EGFRCDK2KDRJAK2AURKB | |
| SCHEMBL24528994 | 0.86 | EGFR (0.86) | EGFRCDK2KDRJAK2AURKB | |
| SCHEMBL29722788 | 0.86 | EGFR (0.86) | EGFRCDK2KDRJAK2AURKB | |
| SCHEMBL29188609 | 0.85 | EGFR (0.75) | EGFRCDK2KDRJAK2AURKB | |
| SCHEMBL30459583 | 0.85 | EGFR (0.75) | EGFRCDK2KDRJAK2AURKB | |
| SCHEMBL20078173 | 0.85 | EGFR (0.75) | EGFRCDK2KDRJAK2AURKB | |
| SCHEMBL24528923 | 0.84 | EGFR (0.86) | EGFRCDK2KDRJAK2AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200308171-A1 | BIFUNCTIONAL INHIBITORS WITH EGFR HAVING A E3 UBIQUITIN LIGASE MOIETY | HOFFMANN-LA ROCHE INC. (US) | 2020-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308171-A1 | BIFUNCTIONAL INHIBITORS WITH EGFR HAVING A E3 UBIQUITIN LIGASE MOIETY | EGFR, ERBB2, MDM2 | EGFR 1/4885CDK2 397/4885KDR 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.